215 FIRST STREET, CAMBRIDGE, MA
Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
Ex-99.1
Sarepta Therapeutics Approves 2026 Equity Incentive Plan at Annual Meeting
Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Annual Report to Security Holders
CEO Departure - Douglas Ingram to Retire by End of 2026
Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Q2
Q1
FY 2025
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Quarterly Holdings Report for Institutional Managers
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
S-8 POS